Skip to content
  • Sunday, 26 July 2026
  • 2:59 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide 
Laboratory Automation & Robotics

Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide 

Lana Keisha Apr 13, 2026 0

A Deep Dive into the Trial Results CagriSema, a novel combination therapy comprising cagrilintide and semaglutide, delivered an average weight…

Read More
Laboratory Automation & Robotics

Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide

Lana Keisha Mar 26, 2026 0

Novo Nordisk’s latest investigational weight loss treatment, CagriSema, has failed to achieve its primary endpoint of demonstrating non-inferiority when compared…

Read More
Laboratory Automation & Robotics

Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide

Lana Keisha Mar 18, 2026 0

Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its investigational weight loss treatment, CagriSema,…

Read More
BioTechniques Announces 2026 Image Competition with Extended Deadline and Enhanced US$500 PrizeStanford Medicine Researchers Discover Glucose Functions as a Master Regulator of Stem Cell Differentiation Beyond Energy ProductionSai Life Sciences’ Biotech Pitch Day 2026 Spotlights Emerging Innovation and Forges Crucial Collaborations in the Drug Discovery LandscapeCornell University Scientists Achieve Breakthrough in Reversible Nonhormonal Male Contraception through Targeted Meiotic Interruption
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ